DOCSLIB.ORG

A Dissertation Entitled Role of Complement Regulatory Proteins

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Dissertation Entitled Role of Complement Regulatory Proteins A dissertation entitled Role of Complement Regulatory Proteins Properdin and Factor H in Platelet/Granulocyte Aggregate Formation by Adam Z. Blatt Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Biomedical Sciences Viviana P. Ferreira, D.V.M., Ph.D., Committee Chair R. Travis Taylor, Ph.D., Committee Member Guillermo Vazquez, Ph.D., Committee Member R. Mark Wooten, Ph.D., Committee Member Randall G. Worth, Ph.D., Committee Member Amanda Bryant-Friedrich, Dr. rer. Nat , Dean College of Graduate Studies The University of Toledo August 2016 Copyright 2016, Adam Z. Blatt This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An abstract of Role of Complement Regulatory Proteins Properdin and Factor H in Platelet/Granulocyte Aggregate Formation by Adam Z. Blatt Submitted to the graduate faculty in partial fulfillment of the requirements for the Doctor of Philosophy Degree in Biomedical Sciences University of Toledo August 2016 Platelet binding to leukocytes is a normal response to vascular damage and inflammation, however excessive platelet/leukocyte interactions have significant pathologic potential due to the ability of platelets to directly stimulate leukocytes. Formation of stable platelet/granulocyte aggregates (PGAs) induces neutrophils to release inflammatory cytokine/chemokines and damaging proteases, produce reactive oxygen species, and upregulate adhesion molecule and tissue factor expression. High levels of circulating PGAs are found in patients with diverse inflammatory vascular diseases, and animal models of vascular injury have shown benefits to limiting PGA formation in vivo. The complement system enhances PGA formation in human blood stimulated with thrombin receptor-activating peptide (TRAP), however precise mechanisms for the effects of complement are unknown. Here, we utilized ex vivo and in vitro flow cytometry assays to show that properdin, a positive regulator, and Factor H (FH), a negative regulator, of the alternative complement pathway (AP) have key roles in controlling the extent of TRAP-mediated PGA formation in human whole blood. Physiological properdin oligomers added exogenously to TRAP-stimulated whole blood iii enhance PGA formation and AP activity, while blocking endogenous properdin function with inhibitory antibodies limits PGA formation. Blocking C5a-C5a receptor interactions limits PGA formation to similar levels seen with inhibition of properdin and abrogates exogenous properdin-mediated increases in PGA formation. C5a directly enhances TRAP-mediated PGA formation and CD11b expression on granulocytes, indicating C5a is the key complement effector molecule for PGA formation. The effects of properdin on PGA formation, are tightly controlled by FH cell-surface protection. FH C-terminal domains 19-20 are key for regulating AP activity on the surface of platelets and neutrophils, and for controlling C5a generation at the platelet/granulocyte interface in TRAP-stimulated blood. Finally, mutations in domains 19-20 associated with atypical hemolytic uremic syndrome (aHUS) have differential effects on the ability of FH to control PGA formation and limit AP activity on platelets and neutrophils, suggesting that increased PGA formation contributes to thrombosis seen in patients with some, but not all, aHUS-related FH mutations. Our work has elucidated critical mechanisms governing PGA formation, and could potentially be used to develop novel therapeutics to limit thromboinflammation in inflammatory diseases. iv For my family, who set me on a path toward my dreams and gave me the courage to follow it v Acknowledgements First and foremost, I would like to thank my family. You have continuously given me the love, support, and guidance that has made me the man I am today and pushed me to pursue the M.D./Ph.D. program. You gave me the strength to realize that nothing in this life is impossible if you set your mind to it. And when life throws me curveballs, you are there to pick me up and get me back on course. To my mentor, Dr. Viviana Ferreira, I give you my deepest thanks for molding me into the scientist I am, today. For all the long hours you spent training me, mentoring me, and ultimately pushing me to strive for excellence in everything I do, I am gracious. For countless hours training me when I joined the lab, I would like to thank Dr. Gurpanna Saggu. Your patience and dedication in training me influenced the entire outlook of my time in the lab. I would also like to thank the other lab members who provided assistance, stimulating conversations, and an enjoyable work atmosphere, especially Heather Emch, Koustubh Kulkarni, and Sean Ehinger. I would like to thank my committee members for their critical feedback and support throughout the duration of my project. Finally, I would like to express my utmost appreciation to all the members of the Department of Medical Microbiology and Immunology, who made it a great place to come to work for the past 3 years, and who helped me to relax and decompress outside the lab. vi Contents Abstract………………………………………………………………………………... iii Acknowledgements……………………………………………………………………. vi Contents……………………………………………………………………………….. vii List of Figures………..……………………………………………………………….. xii List of Abbreviations………………………………………………………………… xvi 1 Introduction…………………………………………………………………………. 1 1.1 The complement system………………………………………………………. 1 1.1.1 Background……………………………………………………………. 1 1.1.2 Mechanisms of activation…………………………………………….. 1 1.1.2.1 The classical pathway………………………………………… 2 1.1.2.2 The lectin pathway…………………………………………… 4 1.1.2.3 The alternative pathway……………………………………… 5 1.1.2.4 The terminal pathway………………………………………… 7 1.1.2.5 The extrinsic pathway………………………………………... 8 1.1.3 Effector functions……………………………………………………... 8 1.1.3.1 The C3 opsonins……………………………………………… 8 1.1.3.2 The anaphylatoxins…………………………………………… 9 1.1.3.3 The MAC……………………………………………………...11 1.1.4 Regulatory proteins………………………………………………….. 11 1.1.4.1 Membrane bound regulatory proteins……………………..... 12 vii 1.1.4.2 Fluid phase regulatory molecules…………………………… 12 1.1.4.2.1 Factor H………………………………………... 13 1.1.4.2.2 Properdin…………………………………………. 17 1.2 Platelets…………………………………………………………...…………... 20 1.2.1 Introduction to platelets…………………………………………………. 20 1.2.2 Complement and platelets………………………………………………. 23 1.3 Neutrophils…………………………………………………………................ 25 1.3.1 Introduction to neutrophils……………………………………………. 25 1.3.2 Complement and neutrophils………………………………………….. 27 1.4 Platelet/granulocyte aggregates……………………………………………... 28 1.4.1 Introduction to platelet/granulocyte aggregates………………………. 28 1.4.2 Physical contacts……………………………………………………… 29 1.4.3 Communication through soluble mediators…………………………... 31 1.4.4 Complement and PGA………………………………………………… 31 2 Hypothesis…………………………………………………………...……………... 32 3 Specific aims…………………………………………………………...…………… 33 4 Materials and Methods…………...……………………………………………...... 35 4.1 Materials…………………………………………………………...…………. 35 4.1.1 Buffers…………………………………………………………...……. 35 4.1.2 Antibodies…………………………………………………………...... 36 4.1.3 Other reagents…………………………………………………………. 37 viii 4.2 Methods…………………………………………………………...………….. 39 4.2.1 Generation of platelet-rich and platelet-poor plasma from half-tube of blood anticoagulated with different direct thrombin inhibitors......... 39 4.2.2 Clotting assay…………………………………………………………. 41 4.2.3 Assessment of effects of direct thrombin inhibitors on platelet aggregation…………………………………………………………..... 41 4.2.4 Assessment of effects of reagents on AP-mediated lysis of rabbit erythrocytes by normal human sera…………………………………… 42 4.2.5 Assessment of effects of anticoagulants on AP-mediated lysis of rabbit erythrocytes by human plasma………………………………...... 43 4.2.6 Separation of physiological properdin forms…………………………. 43 4.2.7 Measurement of TRAP-mediated PLA formation, C3 fragment deposition, and CD11b expression……………………………………. 43 4.2.8 Analysis of C5a levels in PLA reaction supernatants………………… 45 4.2.9 Platelet isolation………………………………………………………. 46 4.2.10 Platelet activation……………………………………………………... 47 4.2.11 Mapping regions of FH that contribute to the regulation of the AP on thrombin-activated platelets…………………………………………... 48 4.2.12 Mapping regions of FH that contribute to the regulation of the AP on arachidonic acid-activated platelets…………………………………… 49 4.2.13 Measurement of effects of rH19-20 mutants on C3 fragment ix deposition on thrombin-activated platelets……………………………. 49 4.2.14 Isolation of neutrophils………………………………………………... 51 4.2.15 Measurement of AP activation on neutrophils………………………... 52 4.3 Statistics…………………………………………………………...………….. 53 5 Results…………………………………………………………...………………….. 54 5.1 Specific aim 1: To determine molecular mechanisms by which properdin enhances PGA formation………………………………………... 54 5.1.1 To assess whether recombinant hirudin is a suitable alternative for lepirudin in whole blood PGA assays……………………………... 54 5.1.2 To determine whether physiological properdin forms increase PGA formation………………………………………………………... 59 5.1.3 To determine whether inhibition of endogenous properdin reduces TRAP-induced PGA formation………………………………. 62 5.1.4 To determine which complement pathways contribute to PGA formation…………………………………………………………...…. 68 5.1.5 To determine how properdin-mediated C5a generation enhances TRAP-mediated PGA formation……………………………………… 70 5.2 Specific aim 2: To determine the role of Factor H in the interaction between platelets and neutrophils…………………………………………..
Load more

Recommended publications
  • MONONINE (“Difficulty ® Monoclonal Antibody Purified in Concentrating”; Subject Recovered)
    CSL Behring IU/kg (n=38), 0.98 ± 0.45 K at doses >95-115 IU/kg (n=21), 0.70 ± 0.38 K at doses >115-135 IU/kg (n=2), 0.67 K at doses >135-155 IU/kg (n=1), and 0.73 ± 0.34 K at doses >155 IU/kg (n=5). Among the 36 subjects who received these high doses, only one (2.8%) Coagulation Factor IX (Human) reported an adverse experience with a possible relationship to MONONINE (“difficulty ® Monoclonal Antibody Purified in concentrating”; subject recovered). In no subjects were thrombo genic complications MONONINE observed or reported.4 only The manufacturing procedure for MONONINE includes multiple processing steps that DESCRIPTION have been designed to reduce the risk of virus transmission. Validation studies of the Coagulation Factor IX (Human), MONONINE® is a sterile, stable, lyophilized concentrate monoclonal antibody (MAb) immunoaffinity chromatography/chemical treatment step and of Factor IX prepared from pooled human plasma and is intended for use in therapy nanofiltration step used in the production of MONONINE doc ument the virus reduction of Factor IX deficiency, known as Hemophilia B or Christmas disease. MONONINE is capacity of the processes employed. These studies were conducted using the rel evant purified of extraneous plasma-derived proteins, including Factors II, VII and X, by use of enveloped and non-enveloped viruses. The results of these virus validation studies utilizing immunoaffinity chromatography. A murine monoclonal antibody to Factor IX is used as an a wide range of viruses with different physicochemical properties are summarized in Table affinity ligand to isolate Factor IX from the source material.
    [Show full text]
  • The Membrane Complement Regulatory Protein CD59 and Its Association with Rheumatoid Arthritis and Systemic Lupus Erythematosus
    Current Medicine Research and Practice 9 (2019) 182e188 Contents lists available at ScienceDirect Current Medicine Research and Practice journal homepage: www.elsevier.com/locate/cmrp Review Article The membrane complement regulatory protein CD59 and its association with rheumatoid arthritis and systemic lupus erythematosus * Nibhriti Das a, Devyani Anand a, Bintili Biswas b, Deepa Kumari c, Monika Gandhi c, a Department of Biochemistry, All India Institute of Medical Sciences, New Delhi 110029, India b Department of Zoology, Ramjas College, University of Delhi, India c University School of Biotechnology, Guru Gobind Singh Indraprastha University, India article info abstract Article history: The complement cascade consisting of about 50 soluble and cell surface proteins is activated in auto- Received 8 May 2019 immune inflammatory disorders. This contributes to the pathological manifestations in these diseases. In Accepted 30 July 2019 normal health, the soluble and membrane complement regulatory proteins protect the host against Available online 5 August 2019 complement-mediated self-tissue injury by controlling the extent of complement activation within the desired limits for the host's benefit. CD59 is a membrane complement regulatory protein that inhibits the Keywords: formation of the terminal complement complex or membrane attack complex (C5b6789n) which is CD59 generated on complement activation by any of the three pathways, namely, the classical, alternative, and RA SLE the mannose-binding lectin pathway. Animal experiments and human studies have suggested impor- Pathophysiology tance of membrane complement proteins including CD59 in the pathophysiology of rheumatoid arthritis Disease marker (RA) and systemic lupus erythematosus (SLE). Here is a brief review on CD59 and its distribution, structure, functions, and association with RA and SLE starting with a brief introduction on the com- plement system, its activation, the biological functions, and relations of membrane complement regu- latory proteins, especially CD59, with RA and SLE.
    [Show full text]
  • Regulation of the Complement System by Pentraxins
    REVIEW published: 02 August 2019 doi: 10.3389/fimmu.2019.01750 Regulation of the Complement System by Pentraxins Karita Haapasalo 1 and Seppo Meri 1,2,3* 1 Department of Bacteriology and Immunology and Translational Immunology Research Program, University of Helsinki, Helsinki, Finland, 2 HUSLAB, Helsinki University Hospital, Helsinki, Finland, 3 Department of Biomedical Sciences, Humanitas University, Milan, Italy The functions of pentraxins, like C-reactive protein (CRP), serum amyloid protein P (SAP) and pentraxin-3 (PTX3), are to coordinate spatially and temporally targeted clearance of injured tissue components, to protect against infections and to regulate related inflammation together with the complement system. For this, pentraxins have a dual relationship with the complement system. Initially, after a focused binding to their targets, e.g., exposed phospholipids or cholesterol in the injured tissue area, or microbial components, the pentraxins activate complement by binding its first component C1q. However, the emerging inflammation needs to be limited to the target area. Therefore, pentraxins inhibit complement at the C3b stage to prevent excessive damage. The complement inhibitory functions of pentraxins are based on their ability to interact with complement inhibitors C4bp or factor H (FH). C4bp binds to SAP, while FH binds to Edited by: both CRP and PTX3. FH promotes opsonophagocytosis through inactivation of C3b to Barbara Bottazzi, Milan University, Italy iC3b, and inhibits AP activity thus preventing formation of the C5a anaphylatoxin and the Reviewed by: complement membrane attack complex (MAC). Monitoring CRP levels gives important Livija Deban, clinical information about the extent of tissue damage and severity of infections. CRP is a Prokarium, United Kingdom valuable marker for distinguishing bacterial infections from viral infections.
    [Show full text]
  • More Than a Pore: Nonlytic Antimicrobial Functions of Downloaded from Complement and Bacterial Strategies for Evasion
    REVIEW More than a Pore: Nonlytic Antimicrobial Functions of Downloaded from Complement and Bacterial Strategies for Evasion Elisabet Bjanes,a Victor Nizeta,b aDivision of Host-Microbe Systems and Therapeutics, Department of Pediatrics, UC San Diego, La Jolla, California, USA bSkaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla, California, USA http://mmbr.asm.org/ SUMMARY ........................................................................1 INTRODUCTION ...................................................................2 BY THE BOOK: CANONICAL COMPLEMENT CASCADES ...............................2 Off to the Races—Pathway Activation . 2 More and More—Amplification . 3 End of the Line—Termination . 3 Pump the Brakes—Inhibition . 5 Surviving MAC Attack—Evasion of Complement Lysis by Gram-Negative Bacteria . 6 NONLYTIC COMPLEMENT FUNCTIONS AND BACTERIAL EVASION MECHANISMS ......8 Special Considerations in Gram-Positive Bacteria . 8 on January 27, 2021 at UNIV OF CALIF SAN DIEGO Preparing the Meal—Complement Aids Opsonization and Phagocytosis . 8 Food for Thought—Complement Traffics to Autophagy . 10 Fueling the Fire—Complement Modulates Inflammatory Responses . 11 Casting a Wider NET—Complement and Neutrophil Synergy . 12 Inside Scoop—Novel Roles of Intracellular Complement . 13 Tying the Clot—Complement and Coagulation Cross Talk . 15 Bridging the Gap—Complement Instructs Adaptive Immunity . 17 REFRAMING SCIENTIFIC PARADIGMS AND THERAPEUTIC APPROACHES TO ENCOMPASS COMPLEMENT ..................................................18
    [Show full text]
  • Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia
    BASIC RESEARCH www.jasn.org Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia Yoshiyasu Ueda,1 Takashi Miwa,1 Damodar Gullipalli,1 Sayaka Sato,1 Daisuke Ito,1 Hangsoo Kim,1 Matthew Palmer,2 and Wen-Chao Song1 Departments of 1Systems Pharmacology and Translational Therapeutics and 2Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania ABSTRACT Background Properdin (P) is a positive regulator of the alternative pathway of complement activation. Although P inhibition is expected and has been shown to ameliorate the alternative pathway of comple- ment-mediated tissue injury in several disease models, it unexpectedly exacerbated renal injury in a murine model of C3 glomerulopathy. The role of P in atypical hemolytic uremic syndrome (aHUS) is uncertain. Methods We blocked P function by genetic deletion or mAb-mediated inhibition in mice carrying a factor H (FH) point mutation, W1206R (FHR/R), that causes aHUS and systemic thrombophilia with high mortality. Results Pdeficiency completely rescued FHR/R mice from premature death and prevented thrombocyto- penia, hemolytic anemia, and renal disease. It also eliminated macrovessel thrombi that were prevalent in FHR/R mice. All mice that received a function-blocking anti-P mAb for 8 weeks survived the experimental period and appeared grossly healthy. Platelet counts and hemoglobin levels were significantly improved in FHR/R mice after 4 weeks of anti-P mAb treatment. One half of the FHR/R mice treated with an isotype control mAb but none of the anti-P mAb-treated mice developed stroke-related neurologic disease. Anti-P mAb-treated FHR/R mice showed largely normal renal histology, and residual liver thrombi were detected in only three of 15 treated mice.
    [Show full text]
  • Nephrology Clinical Laboratory Research Compendium
    Nephrology Clinical Laboratory Research Compendium The Nephrology Clinical Laboratory at Cincinnati Children’s Hospital Medical Center has expanded its clinical testing menu to now offer testing on a research basis. The CAP and CLIA certified laboratory operates under Good Clinical Laboratory Practice principles to ensure testing can be used to support findings of clinical trials. CONTACT US Our state of the art laboratory offers a broad testing menu to support research and pharmaceutical projects. We have the capability to perform traditional For more information on research or ELISA’S, multiplexing using the MSD Meso discovery, luminex magnetic bead clinical testing, please contact us at: assays, nephelometry and clinical chemistry. Phone: 513-636-4530 [email protected] The Nephrology Clinical Laboratory Research Compendium offers clinical chemistry, therapeutic drug monitoring, immunology, complement quantitation, www.cincinnatichildrens.org function and activation, specialty proteins and testing for various forms of thrombotic microangiopathies. COMPLEMENT SPECIALTY TESTING Autoantibody Testing Complement Components • Factor H Autoantibody (Quantitative) • C3 Nephritic Factor • C1 inhibitor (quantitative) • Factor B Autoantibody • C1q • C2 Functional Testing • C3 • CH50 • C4 • Alternative Pathway Functional Assay • C5 • MBL Pathway Functional Assay • C6 • C1 inhibitor Functional Assay • C7 • C8 Complement Activation Fragments • C9 • Complement Bb • Factor B • Complement Ba • Factor H • C3a • Factor I • C3c • Properdin • C3d
    [Show full text]
  • By Map44 Pathway Activation in a Manner Inhibitable Pattern
    Co-Complexes of MASP-1 and MASP-2 Associated with the Soluble Pattern-Recognition Molecules Drive Lectin Pathway Activation in a Manner Inhibitable This information is current as by MAp44 of September 28, 2021. Søren E. Degn, Lisbeth Jensen, Tomasz Olszowski, Jens C. Jensenius and Steffen Thiel J Immunol 2013; 191:1334-1345; Prepublished online 19 June 2013; Downloaded from doi: 10.4049/jimmunol.1300780 http://www.jimmunol.org/content/191/3/1334 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2013/06/19/jimmunol.130078 Material 0.DC1 References This article cites 43 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/191/3/1334.full#ref-list-1 Why The JI? Submit online. by guest on September 28, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Co-Complexes of MASP-1 and MASP-2 Associated with the Soluble Pattern-Recognition Molecules Drive Lectin Pathway Activation in a Manner Inhibitable by MAp44 Søren E.
    [Show full text]
  • Are Complement Deficiencies Really Rare?
    G Model MIMM-4432; No. of Pages 8 ARTICLE IN PRESS Molecular Immunology xxx (2014) xxx–xxx Contents lists available at ScienceDirect Molecular Immunology j ournal homepage: www.elsevier.com/locate/molimm Review Are complement deficiencies really rare? Overview on prevalence, ଝ clinical importance and modern diagnostic approach a,∗ b Anete Sevciovic Grumach , Michael Kirschfink a Faculty of Medicine ABC, Santo Andre, SP, Brazil b Institute of Immunology, University of Heidelberg, Heidelberg, Germany a r a t b i c s t l e i n f o r a c t Article history: Complement deficiencies comprise between 1 and 10% of all primary immunodeficiencies (PIDs) accord- Received 29 May 2014 ing to national and supranational registries. They are still considered rare and even of less clinical Received in revised form 18 June 2014 importance. This not only reflects (as in all PIDs) a great lack of awareness among clinicians and gen- Accepted 23 June 2014 eral practitioners but is also due to the fact that only few centers worldwide provide a comprehensive Available online xxx laboratory complement analysis. To enable early identification, our aim is to present warning signs for complement deficiencies and recommendations for diagnostic approach. The genetic deficiency of any Keywords: early component of the classical pathway (C1q, C1r/s, C2, C4) is often associated with autoimmune dis- Complement deficiencies eases whereas individuals, deficient of properdin or of the terminal pathway components (C5 to C9), are Warning signs Prevalence highly susceptible to meningococcal disease. Deficiency of C1 Inhibitor (hereditary angioedema, HAE) Meningitis results in episodic angioedema, which in a considerable number of patients with identical symptoms Infections also occurs in factor XII mutations.
    [Show full text]
  • Regulation of Decay Accelerating Factor Primes Human Germinal Center B Cells for Phagocytosis
    ORIGINAL RESEARCH published: 05 January 2021 doi: 10.3389/fimmu.2020.599647 Regulation of Decay Accelerating Factor Primes Human Germinal Center B Cells for Phagocytosis Andy Dernstedt 1, Jana Leidig 1, Anna Holm 2, Priscilla F. Kerkman 1, Jenny Mjösberg 3, Clas Ahlm 1, Johan Henriksson 4, Magnus Hultdin 5 and Mattias N. E. Forsell 1* 1 Department of Clinical Microbiology, Section of Infection and Immunology, Umeå University, Umeå, Sweden, 2 Department of Clinical Sciences, Division of Otorhinolaryngology, Umeå University, Umeå, Sweden, 3 Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 4 Molecular Infection Medicine Sweden, Department of Molecular Biology, Umeå University, Umeå, Sweden, 5 Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden Germinal centers (GC) are sites for extensive B cell proliferation and homeostasis is maintained by programmed cell death. The complement regulatory protein Decay Edited by: Accelerating Factor (DAF) blocks complement deposition on host cells and therefore Judith Fraussen, also phagocytosis of cells. Here, we show that B cells downregulate DAF upon BCR University of Hasselt, Belgium lo Reviewed by: engagement and that T cell-dependent stimuli preferentially led to activation of DAF B lo Paolo Casali, cells. Consistent with this, a majority of light and dark zone GC B cells were DAF and University of Texas Health Science susceptible to complement-dependent phagocytosis, as compared with DAFhi GC B Center at San Antonio, United States hi Shengli Xu, cells. We could also show that the DAF GC B cell subset had increased expression of the Bioprocessing Technology Institute plasma cell marker Blimp-1.
    [Show full text]
  • Coagulation Factors Directly Cleave SARS-Cov-2 Spike and Enhance Viral Entry
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.31.437960; this version posted April 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry. Edward R. Kastenhuber1, Javier A. Jaimes2, Jared L. Johnson1, Marisa Mercadante1, Frauke Muecksch3, Yiska Weisblum3, Yaron Bram4, Robert E. Schwartz4,5, Gary R. Whittaker2 and Lewis C. Cantley1,* Affiliations 1. Meyer Cancer Center, Department of Medicine, Weill Cornell Medical College, New York, NY, USA. 2. Department of Microbiology and Immunology, Cornell University, Ithaca, New York, USA. 3. Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. 4. Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA. 5. Department of Physiology, Biophysics and Systems Biology, Weill Cornell Medicine, New York, NY, USA. *Correspondence: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2021.03.31.437960; this version posted April 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Summary Coagulopathy is recognized as a significant aspect of morbidity in COVID-19 patients. The clotting cascade is propagated by a series of proteases, including factor Xa and thrombin. Other host proteases, including TMPRSS2, are recognized to be important for cleavage activation of SARS-CoV-2 spike to promote viral entry. Using biochemical and cell-based assays, we demonstrate that factor Xa and thrombin can also directly cleave SARS-CoV-2 spike, enhancing viral entry.
    [Show full text]
  • LP Review Published.Pdf
    Molecular Immunology 56 (2013) 413–422 Contents lists available at SciVerse ScienceDirect Molecular Immunology jo urnal homepage: www.elsevier.com/locate/molimm Review Toward a structure-based comprehension of the lectin pathway of complement a a b,∗ Troels R. Kjaer , Steffen Thiel , Gregers R. Andersen a Department of Biomedicine, Aarhus University, Wilhelm Meyers Allé 4, DK-8000 Aarhus, Denmark b Department of Molecular Biology and Genetics, Aarhus University, Gustav Wieds Vej 10C, DK-8000 Aarhus, Denmark a r t a b i c l e i n f o s t r a c t Article history: To initiate the lectin pathway of complement pattern recognition molecules bind to surface-linked car- Received 2 May 2013 bohydrates or acetyl groups on pathogens or damaged self-tissue. This leads to activation of the serine Accepted 14 May 2013 proteases MASP-1 and MASP-2 resulting in deposition of C4 on the activator and assembly of the C3 convertase. In addition MASP-3 and the non-catalytic MAp19 and MAp44 presumably play regulatory Keywords: functions, but the exact function of the MASP-3 protease remains to be established. Recent functional Complement system studies have significantly advanced our understanding of the molecular events occurring as activation Pattern recognition progresses from pattern recognition to convertase assembly. Furthermore, atomic structures derived MBL MASP by crystallography or solution scattering of most proteins acting in the lectin pathway and two key complexes have become available. Here we integrate the current functional and structural knowledge Protease activation C4 concerning the lectin pathway proteins and derive overall models for their glycan bound complexes.
    [Show full text]
  • Widely Used Commercial Elisa Does Not Detect Precursor of Haptoglobin2, but Recognizes Properdin As a Potential Second Member of the Zonulin Family
    ORIGINAL RESEARCH published: 05 February 2018 doi: 10.3389/fendo.2018.00022 Widely Used Commercial ELISA Does Not Detect Precursor of Haptoglobin2, but Recognizes Properdin as a Potential Second Member of the Zonulin Family Lucas Scheffler1, Alyce Crane1, Henrike Heyne1, Anke Tönjes2, Dorit Schleinitz1, Christian H. Ihling3, Michael Stumvoll2, Rachel Freire4, Maria Fiorentino4, Alessio Fasano4, Peter Kovacs1* and John T. Heiker5* 1 Leipzig University Medical Center, IFB Adiposity Diseases, Leipzig, Germany, 2 Divisions of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany, 3 Department of Pharmaceutical Chemistry and Bioanalytics, Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Halle, Germany, 4 Mucosal Immunology And Biology Research Center, Massachusetts General Hospital––Harvard Medical School, Boston, MA, United States, 5 Faculty of Biosciences, Pharmacy and Psychology, Institute of Biochemistry, University of Leipzig, Leipzig, Germany Background: There is increasing evidence for the role of impaired intestinal permeability Edited by: in obesity and associated metabolic diseases. Zonulin is an established serum marker for Dr Saumen Kumar Maitra, Visva-Bharati University, India intestinal permeability and identical to pre-haptoglobin2. Here, we aimed to investigate Reviewed by: the relationship between circulating zonulin and metabolic traits related to obesity. Yicong Li, Johns Hopkins Medicine, Methods: Serum zonulin was measured by using a widely used commercial ELISA kit in United States 376 subjects from the metabolically well-characterized cohort of Sorbs from Germany. In Asamanja Chattoraj, addition, haptoglobin genotype was determined in DNA samples from all study subjects. Institute of Bio-Resources and Sustainable Development, India Results: As zonulin concentrations did not correlate to the haptoglobin genotypes, *Correspondence: we investigated the specificity of the zonulin ELISA assay using antibody capture John T.
    [Show full text]